ROCKVILLE, Md., March 13 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced its 2008 corporate and clinical program priorities. Formal remarks regarding corporate objectives, as well as plans for current and future clinical development milestones were delivered this morning by EntreMed President and CEO, James S. Burns, during the Company's year-end 2007 update call.
EntreMed reiterated its strategy of investing behind multiple clinical-
stage oncology product candidates. In 2008, EntreMed plans to focus in
three principal objectives.
-- Concentrate resources on fewer programs that provide a more direct path
forward to product registration and ultimately to the market;
-- Conserve cash by funding essential priority program activities and
deferring new program initiatives; and
-- Expand partnering activities across multiple clinical programs.
EntreMed also announced that the Company has reprioritized its
development pipeline to focus investment on three of its oncology programs,
specifically: MKC-1, ENMD-1198, and ENMD-2076.
-- MKC-1 is a novel, orally-active cell cycle inhibitor with broad-acting
antitumor activity, including tumor growth inhibition or regression in
multiple preclinical models. MKC-1 has been shown to inhibit the PI3K
Akt-mTOR signaling pathway, which occurs through inhibition of the
mTOR/rictor branch of the pathway. MKC-1 was
|SOURCE EntreMed, Inc.|
Copyright©2008 PR Newswire.
All rights reserved